Using transcriptomic profiling, bioinformatic analyses, and structural modeling, we found that E2F1 orchestrates the tumor niche by activating an IL6-based gene regulatory network (GRN) and a highly inflammatory secretome. The gene discussed is E2F1; the disease is neoplasm.